Opiates

Dose and frequency are the dominant variables. A single therapeutic dose of morphine or codeine for acute pain typically clears the SAMHSA 2000 ng/mL urinary cutoff within 24 to 48 hours. Chronic high-dose use — patients on long-standing extended-release morphine for cancer pain, for example, or individuals using heroin daily — can remain positive for three to five days after the last dose. The opiates analyte does not produce a long tissue tail the way THC does because morphine and codeine are not appreciably lipophilic; the detection window is governed primarily by the drug and metabolite elimination half-lives.

Route of administration affects pharmacokinetic peaks but has limited effect on urinary detection. Intravenous morphine and inhaled or injected heroin produce rapid and high plasma peaks; oral morphine, codeine tablets, and codeine combination products produce slower and lower peaks; transdermal and parenteral formulations vary. All routes converge on the same hepatic metabolic pathways and produce morphine, normorphine, morphine glucuronides, and (for codeine) codeine plus morphine in urine. The relative ratios of these compounds on confirmation testing can help distinguish codeine use from morphine use.

Hepatic metabolism is the primary clearance pathway. Codeine is metabolized to morphine by CYP2D6, which is genetically polymorphic — poor metabolizers convert little codeine to morphine and may have inadequate analgesia, while ultra-rapid metabolizers convert more and have a higher risk of opioid toxicity. Morphine itself is conjugated to morphine-3-glucuronide (inactive) and morphine-6-glucuronide (active) by UGT2B7. Hepatic impairment from cirrhosis or hepatitis prolongs clearance of all opioids and can extend the detection window.

Renal function is important because morphine glucuronides are renally eliminated. Patients with chronic kidney disease accumulate morphine-6-glucuronide, which both extends pharmacologic effect and prolongs the urinary detection of opiate metabolites. This is clinically relevant in older patients, dialysis patients, and critical-care settings where renal function may fluctuate. Body composition has minimal effect on opiate detection. Age and concurrent medications (particularly other CYP2D6 substrates or inhibitors for codeine users) play smaller modifying roles.

SAMHSA's Mandatory Guidelines for Federal Workplace Drug Testing Programs set the initial immunoassay cutoff for opiates at 2000 ng/mL of morphine in urine, raised from 300 ng/mL in the 2017 guidelines update. The confirmation cutoff by GC/MS or LC-MS/MS is also 2000 ng/mL for morphine and codeine. The 2017 increase was specifically intended to reduce false positives from dietary poppy-seed consumption, which had produced legitimate clinical and regulatory concerns under the older threshold.

In parallel, SAMHSA requires that every specimen positive for the opiates analyte also be tested for 6-monoacetylmorphine (6-MAM) at a 10 ng/mL initial and 10 ng/mL confirmation cutoff. The presence of 6-MAM is unambiguous evidence of heroin use, independent of the morphine concentration, because 6-MAM is not produced by any dietary or pharmaceutical exposure. A donor positive for morphine above 2000 ng/mL but negative for 6-MAM may be using prescription morphine or, less commonly, may have consumed unusually large amounts of poppy seeds; a donor positive for 6-MAM has used heroin.

Non-federal employers and clinical programs are free to set their own cutoffs. Many treatment programs and some workplace programs retain the older 300 ng/mL cutoff for greater sensitivity to recent use, accepting the higher rate of poppy-seed-related positives as the trade-off. SAMHSA's oral-fluid guidelines specify a 30 ng/mL cutoff for opiates (morphine, codeine) and a 4 ng/mL cutoff for 6-MAM, with the same overall analytic logic. Hair testing is not yet a SAMHSA-authorized matrix; commercial laboratories typically use 200 pg/mg for morphine and codeine on hair with mass-spectrometric confirmation.

Lateral-flow immunoassay is the standard format for point-of-care opiates screening. The test strip contains a membrane impregnated with antibodies raised against morphine and a colored conjugate. When urine wicks up the strip, free morphine and structurally similar opiates from the sample compete with the labeled conjugate for antibody binding sites; sufficient analyte at or above the device cutoff produces a no-test-line positive result. The control line confirms reagent function. All Magenta dip cards and cups use this format and produce a read in approximately five minutes.

Cross-reactivity within the natural and semi-synthetic opiate family is the design intent of the assay. Anti-morphine antibodies cross-react with codeine, morphine glucuronides, hydromorphone, 6-MAM, and to varying degrees other structurally similar opiate compounds — which is appropriate because the opiates analyte is designed to be a class screen rather than a single-compound assay. What the opiates antibody does NOT cross-react with reliably is the structurally distinct synthetic opioids: oxycodone, hydrocodone (variable, often poor at standard cutoffs), methadone, buprenorphine, fentanyl, and tramadol. Each of these requires its own dedicated immunoassay, and any program that wants coverage for them must include those analytes as separate panel positions.

The 6-MAM analyte is operationally critical for distinguishing heroin use from prescription opiate use or poppy-seed exposure. 6-MAM is a unique heroin metabolite — it is not produced by any other clinical or dietary exposure — so its presence in any specimen at the 10 ng/mL cutoff is unambiguous evidence of heroin use. The short half-life of 6-MAM means a negative 6-MAM result does not exclude heroin use beyond the prior 24 hours or so, but a positive 6-MAM result is essentially diagnostic. SAMHSA-compliant laboratories test for 6-MAM on every opiates-positive specimen.

Confirmation testing by GC/MS or LC-MS/MS is the gold standard for resolving any presumptive positive. SAMHSA-certified laboratories perform confirmation on every screening positive in federally regulated programs and quantify morphine, codeine, and 6-MAM precisely. A Medical Review Officer reviews confirmed positives against documented prescriptions (morphine, codeine combination products, codeine cough preparations) and against any documented relevant dietary exposure (poppy-seed-containing foods consumed in unusual quantities), and verifies that the laboratory analyzed for 6-MAM as required.

Specimen validity testing accompanies every opiates screen. Laboratories and point-of-care devices check creatinine and specific gravity to identify dilute specimens, pH to identify adulteration, and oxidizing-agent panels to identify products marketed to defeat drug tests. Magenta's adulteration-panel cups include creatinine, pH, specific gravity, glutaraldehyde, nitrite, and oxidant pads. A positive adulteration finding generally triggers a refusal-to-test consequence under federal rules, equivalent to a confirmed positive.